Machine Learning for Population PK Model Selection: Theory and Practice
Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…
Danielle Pillsbury2025年2月7日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies
This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…
Danielle Pillsbury2025年2月6日
Understanding Variability in CAR-T Cell Therapy Kinetics
Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…
Danielle Pillsbury2025年1月23日
Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses
This Frontiers in Pharmacology article investigates how using different time-averaged exposure metrics, specifically the time-averaged…
Danielle Pillsbury2025年1月21日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)
In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…
Danielle Pillsbury2025年1月9日
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease
The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…
Danielle Pillsbury2025年1月8日
Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development
At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…
Certara2024年12月10日
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation
This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…
Danielle Pillsbury2024年12月9日
